The completion of the trial allows Lilly to seek regulatory approval and potentially launch the next-generation drug in 2027 as it competes with Novo Nordisk in the obesity treatment market
Wegovy is not recommended for individuals with: A personal or family history of medullary thyroid carcinoma Multiple endocrine neoplasia syndrome type 2 Known hypersensitivity to semaglutide or any of Wegovys ingredients How soon will I see weight loss results with Wegovy
That leads to a cycle of symptoms going up and down rather than gradually improving over time. Thats why doctors recommend increasing the dosage gradually, which allows your body to get used to the medication while keeping weight loss on track
Through laboratoryexperimentationon various animals, including rodents, pigs, dogs, and humans, the unique mechanism of AOD-9604 has been identified, which primarily stimulates the release of fat from adipose tissue, inhibits the accumulation of new fat in adipocytes, and promotes fat oxidation
Most events were mild to moderate and occurred during dose escalation
